according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

SECTION 1. IDENTIFICATION

Product name : Gentamicin / Posaconazole / Mometasone Suspension For-

mulation

Other means of identification : Mometamax Ultra Ear Drops Suspension for Dogs (91464)

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Reproductive toxicity : Category 1A

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H360Df May damage the unborn child. Suspected of damaging

fertility.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P280 Wear protective gloves, protective clothing, eye protection

and face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone **Suspension Formulation**

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
White mineral oil (petroleum)	8042-47-5	>= 90 - <= 100
Gentamicin	1403-66-3	>= 0.1 - < 1
Posaconazole	171228-49-2	>= 0.1 - < 1
Mometasone	83919-23-7	>= 0.1 - < 1

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse. : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

If swallowed

Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and delayed

In case of eye contact

May damage the unborn child. Suspected of damaging

fertility.

Protection of first-aiders First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec: :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe vapors or spray mist.

Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
White mineral oil (petroleum)	8042-47-5	TWA (Mist)	5 mg/m³	OSHA Z-1	
		TWA (Inhalable particulate matter)	5 mg/m³	ACGIH	
		TWA (Mist)	5 mg/m³	NIOSH REL	
		ST (Mist)	10 mg/m ³	NIOSH REL	
Gentamicin	1403-66-3	TWA	0.1 mg/m3 (OEB 2)	Internal	
	Further information: OTO				
Posaconazole	171228-49-2	TWA	300 μg/m3 (OEB 2)	Internal	
Mometasone	83919-23-7	TWA	1 μg/m3 (OEB 4)	Internal	
	Further information: Skin				
		Wipe limit	10 μg/100 cm ²	Internal	

Engineering measures : All engineering controls should be implemented by facility

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to

maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

by air purifying respirators against exposure to any

hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Appearance : suspension

Color : white to off-white

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : 0.874 g/cm³

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

White mineral oil (petroleum):

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Assessment: The substance or mixture has no acute inhala-

tion toxicity

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Assessment: The substance or mixture has no acute dermal

toxicity

Gentamicin:

Acute oral toxicity : LD50 (Rat): 8,000 - 10,000 mg/kg

LD50 (Mouse): 10,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0.2 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Remarks: No mortality observed at this dose.

Acute toxicity (other routes of :

administration)

LD50 (Rat): 67 - 96 mg/kg

Application Route: Intravenous

LD50 (Rat): 371 - 384 mg/kg Application Route: Intramuscular

LDLo (Monkey): 30 mg/kg Application Route: Intravenous

Posaconazole:

Acute oral toxicity LD50 (Rat): > 5,000 mg/kg

LD50 (Mouse): > 3,000 mg/kg

Acute dermal toxicity LD50 (Rat): > 2,000 mg/kg

Mometasone:

Acute oral toxicity LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity LC50 (Rat): > 3.3 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute toxicity (other routes of :

administration)

LD50 (Rat): 300 mg/kg

Application Route: Subcutaneous Symptoms: Breathing difficulties

Skin corrosion/irritation

Not classified based on available information.

Components:

White mineral oil (petroleum):

Species Rabbit

Result No skin irritation

Gentamicin:

Species Rabbit

Result Mild skin irritation

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Posaconazole:

Species : Rabbit

Result : No skin irritation

Mometasone:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

White mineral oil (petroleum):

Species : Rabbit

Result : No eye irritation

Gentamicin:

Species : Rabbit

Result : Mild eye irritation

Posaconazole:

Species : Rabbit

Result : Mild eye irritation

Mometasone:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

White mineral oil (petroleum):

Test Type : Buehler Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Gentamicin:

Remarks : No data available

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Posaconazole:

Test Type : Magnusson-Kligman-Test

Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Mometasone:

Test Type : Maximization Test

Routes of exposure : Dermal Species : Guinea pig

Assessment : Does not cause skin sensitization.

Result : negative

Remarks : The results of a test on guinea pigs showed this substance to

be a weak skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:

White mineral oil (petroleum):

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection Method: OECD Test Guideline 474

Result: negative

Remarks: Based on data from similar materials

Gentamicin:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: equivocal

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intravenous injection

Result: negative

Posaconazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow Application Route: Intravenous

Result: negative

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: positive

Test Type: Mouse Lymphoma

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Test Type: Chromosomal aberration

Species: Rat

Cell type: Bone marrow

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:

White mineral oil (petroleum):

Species : Rat
Application Route : Ingestion
Exposure time : 24 Months
Result : negative

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Gentamicin:

Carcinogenicity - Assess-

ment

No data available

Posaconazole:

Species : Rat
Application Route : oral (feed)
Exposure time : 2 Years
Result : positive

Remarks : The mechanism or mode of action is not relevant in humans.

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : positive

Remarks : The mechanism or mode of action is not relevant in humans.

Mometasone:

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years

Dose : 0.067 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Inhalation
Exposure time : 19 Months

Dose : 0.160 mg/kg body weight

Result : negative

IARC No ingredient of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

OSHANo component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:

White mineral oil (petroleum):

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Skin contact

Result: negative

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

Gentamicin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Fertility: NOAEL: 20 mg/kg body weight

Result: No significant adverse effects were reported

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rabbit

Developmental Toxicity: NOAEL: 3.6 mg/kg body weight

Result: No embryo-fetal toxicity.

Test Type: Embryo-fetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 75 mg/kg body weight

Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development

Species: Mouse

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: Fetal mortality., No malformations were observed.

Test Type: Embryo-fetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 50 mg/kg body weight Result: Fetal mortality., No malformations were observed.

Reproductive toxicity - As-

sessment

Positive evidence of adverse effects on development from

human epidemiological studies.

Posaconazole:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, male

General Toxicity Parent: NOAEL: 180 mg/kg body weight

Symptoms: No effects on mating performance.

Result: negative

Test Type: Fertility/early embryonic development

Species: Rat, female

General Toxicity Parent: NOAEL: 45 mg/kg body weight

Symptoms: No effects on mating performance.

Result: negative

Effects on fetal development : Test Type: Embryo-fetal development

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Species: Rat, female Application Route: Oral

Developmental Toxicity: LOAEL: 29 mg/kg body weight Result: Fetotoxicity., Malformations were observed.

Test Type: Embryo-fetal development

Species: Rabbit, female

Developmental Toxicity: LOAEL: 40 mg/kg body weight

Result: Fetotoxicity.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

Mometasone:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Subcutaneous

Fertility: NOAEL: 0.015 mg/kg body weight

Symptoms: Reduced embryonic survival, Reduced fetal

weight.

Result: No effects on fertility., Effect on reproduction capacity.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Mouse

Application Route: Subcutaneous

Embryo-fetal toxicity.: LOAEL: 0.06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and

developmental toxicity

Test Type: Embryo-fetal development

Species: Rat

Application Route: Dermal

Embryo-fetal toxicity.: LOAEL: 0.3 mg/kg body weight

Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development

Species: Rabbit

Application Route: Dermal

Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight Result: Embryo-fetal toxicity., Malformations were observed.

Test Type: Embryo-fetal development

Species: Rat

Application Route: Subcutaneous

Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight

Result: Effects on newborn.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Embryo-fetal toxicity.: LOAEL: 0.7 mg/kg body weight Result: Embryo-fetal toxicity., Malformations were observed.

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Reproductive toxicity - As-

sessment

: Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT-single exposure

Not classified based on available information.

Components:

Mometasone:

Remarks : Based on available data, the classification criteria are not met.

STOT-repeated exposure

Not classified based on available information.

Components:

Gentamicin:

Target Organs : Kidney, inner ear

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Posaconazole:

Routes of exposure : Ingestion

Target Organs : Adrenal gland, Bone marrow, Kidney, Liver, Reproductive

organs, Nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Mometasone:

Routes of exposure : inhalation (dust/mist/fume)

Target Organs : Immune system, Liver, Kidney, Skin

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

White mineral oil (petroleum):

Species : Rat
LOAEL : 160 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Species : Rat LOAEL : >= 1 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 4 Weeks

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Method : OECD Test Guideline 412

Gentamicin:

Species : Dog
LOAEL : 3 mg/kg
Application Route : Intramuscular
Exposure time : 12 Months
Target Organs : Kidney

Symptoms : Vomiting, Salivation

Species : Monkey
LOAEL : 50 mg/kg
Application Route : Subcutaneous
Exposure time : 3 Weeks

Target Organs : Kidney, inner ear

Species : Monkey
LOAEL : 6 mg/kg
Application Route : Intramuscular
Exposure time : 3 Weeks

Target Organs : Blood, Kidney, inner ear, Liver

Species : Rat

NOAEL : 5 mg/kg

LOAEL : 10 mg/kg

Application Route : Intramuscular

Exposure time : 52 Weeks

Target Organs : Kidney, Blood

Species : Rat

NOAEL : 12.5 mg/kg
LOAEL : 50 mg/kg
Application Route : Intramuscular
Exposure time : 13 Weeks
Target Organs : Kidney

Posaconazole:

Species : Rat, female
LOAEL : 5 mg/kg
Application Route : Oral
Exposure time : 6 Months

Target Organs : Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary

Species : Dog LOAEL : 3 mg/kg Application Route : Oral Exposure time : 392 Days

Target Organs : Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal

cord, lymphoid tissue

Species : Monkey

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

LOAEL : 15 mg/kg Application Route : Oral Exposure time : 1 Months

Target Organs : Bone marrow, Adrenal gland, Lymph nodes, Blood

Species : Dog
LOAEL : 3 mg/kg
Application Route : Oral
Exposure time : 56 Weeks

Target Organs : Adrenal gland, Bone marrow, Kidney, Nervous system,

spleen, thymus gland, Testis, lymphoid tissue

Species : Monkey
LOAEL : 180 mg/kg
Application Route : Oral
Exposure time : 12 Months

Target Organs : Blood, Gastrointestinal tract, spleen

Species : Monkey
LOAEL : 8 mg/kg
Application Route : Intravenous
Exposure time : 1 Months

Target Organs : Cardio-vascular system, Lungs, Adrenal gland, Blood

Mometasone:

Species : Rat

NOAEL : 0.005 mg/kg
LOAEL : 0.3 mg/kg
Application Route : Oral
Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat

NOAEL : 0.00013 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, Liver, thymus gland

Species : Dog

NOAEL : 0.0005 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, thymus gland, Liver

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Aspiration toxicity

Not classified based on available information.

Components:

Mometasone:

Not applicable

Experience with human exposure

Components:

Gentamicin:

Ingestion : Target Organs: Kidney

Target Organs: inner ear

Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal

deafness

Posaconazole:

Ingestion : Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver

effects, Rash, pruritis, Diarrhea, hypertension, neutropenia,

electrolyte imbalance

Mometasone:

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper res-

piratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

Further information

Components:

Mometasone:

Remarks : Dermal absorption possible

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

White mineral oil (petroleum):

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic : NOEC (Pseudokirchneriella subcapitata (green algae)): 100

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

plants mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Oncorhynchus mykiss (rainbow trout)): 1,000 mg/l

Exposure time: 28 d

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 1,000 mg/l

Exposure time: 21 d

Gentamicin:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 86 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

LC50 (Americamysis): 30 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 10 μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 1.5

μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): 4.7 µg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: 288.7 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Posaconazole:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.276 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): >

0.509 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.206 mg/l

Exposure time: 33 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.244 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility.

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l

Exposure time: 7 d

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 5 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility.

EC50 (Americamysis): > 5 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aguatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.00014

mg/l

Exposure time: 32 d

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Method: OECD Test Guideline 210

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.34 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility.

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility.

Persistence and degradability

Components:

White mineral oil (petroleum):

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 31 % Exposure time: 28 d

Gentamicin:

Biodegradability : Result: rapidly degradable

Biodegradation: 100 % Exposure time: 28 d

Method: OECD Test Guideline 314

Posaconazole:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 28 h

Method: OECD Test Guideline 314

Stability in water : Degradation half life (DT50): > 30 d

Method: OECD Test Guideline 111

Mometasone:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 28 d

Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Method: OECD Test Guideline 111

Bioaccumulative potential

Components:

Gentamicin:

Partition coefficient: n-

octanol/water

: log Pow: < -2

Posaconazole:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Bioconcentration factor (BCF): 20 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

: log Pow: 4.15

Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Bioconcentration factor (BCF): 107.1 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 4.68

Mobility in soil

Components:

Posaconazole:

Distribution among environ-

mental compartments

log Koc: 5.52

Mometasone:

Distribution among environ-

mental compartments

: log Koc: 4.02

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

UNRTDG

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Mometasone, Gentamicin)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.

(Mometasone, Gentamicin)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo : 964

aircraft)

Packing instruction (passen: 964

ger aircraft)

Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Mometasone, Gentamicin)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

UN/ID/NA number : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.

(Mometasone, Gentamicin)

Class : 9
Packing group : III
Labels : CLASS 9
ERG Code : 171

Marine pollutant : yes(Mometasone, Gentamicin)

Remarks : Above applies only to containers over 119 gallons or 450

liters.

Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Reproductive toxicity

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

White mineral oil (petroleum) 8042-47-5 Polyethylene 9002-88-4

California Prop. 65

WARNING: This product can expose you to chemicals including Gentamicin, which is/are known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.

California List of Hazardous Substances

White mineral oil (petroleum) 8042-47-5

California Permissible Exposure Limits for Chemical Contaminants

White mineral oil (petroleum) 8042-47-5

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information


according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

NFPA 704:



Special hazard

HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL : USA. NIOSH Recommended Exposure Limits

OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lim-

its for Air Contaminants

ACGIH / TWA : 8-hour, time-weighted average

NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour

workday during a 40-hour workweek

NIOSH REL / ST : STEL - 15-minute TWA exposure that should not be exceeded

at any time during a workday

OSHA Z-1 / TWA : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization: ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable

according to the OSHA Hazard Communication Standard



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 11/20/2023 5.10 09/28/2024 1244512-00022 Date of first issue: 01/27/2017

Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 09/28/2024

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8